Fundraising Fox
Immunophotonics, Inc.
St. Louis, US · Founded 2012 · Delaware corporation · 18 employees on LinkedIn · 6 known investors
Find your way into Immunophotonics, Inc.
Sign up to see every warm intro you have to Immunophotonics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunophotonics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.
Founders & leadership
Board
Investors · 6
How we know: BioGenerator Ventures's portfolio page · Not right? Tell us
How we know: Centennial Investors's portfolio page · Not right? Tell us
How we know: iSelect Fund's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Missouri Technology Corporation's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · press coverage · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$17.6M disclosed across 4 rounds · 2014–2025
▶$10.1MraisedSep 2026 · 45 investors · PharmaceuticalsRule 506(b)
- Alexander Michael HurstExecutive Officer
- Robert H. ArchExecutive Officer
- Miguel M. ZubizarretaDirector
- Luciano AlleruzzoDirector, Promoter
- Jonathan KnowlesDirector
- Wei ChenDirector, Promoter
- Jacqueline HessDirector
- Richard LevensonDirector
- Amount sold
- $10.1M
- Minimum investment
- $100K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2024 · 17 investors · PharmaceuticalsRule 506(b)
- Bobby W. SandageDirector
- Wei R. ChenDirector, Promoter
- Miguel ZubizarretaDirector
- Charlie BoltenDirector
- Tomas HodeExecutive Officer, Director, Promoter
- Jonathan KnowlesDirector
- Luciano AlleruzzoExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $1.5M
- Minimum investment
- $25K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b
▶$3.5MraisedFeb 2023 · 22 investors · PharmaceuticalsRule 506(b)
- Luciano AlleruzzoExecutive Officer, Director, Promoter
- Tomas HodeExecutive Officer, Director, Promoter
- Jonathan KnowlesDirector
- Miguel ZubizarretaDirector
- Charlie BoltenDirector
- Wei R. ChenDirector, Promoter
- Bobby W. SandageDirector
- Offering amount
- $6.5M
- Amount sold
- $3.5M
- Minimum investment
- $50K
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b
▶$2.5MraisedJan 2015 · 28 investors · BiotechnologyRule 506(b)
- David SmollerDirector
- Charlie BoltenDirector
- Tomas HodeExecutive Officer, Director
- Bobby SandageDirector
- Robert E. NordquistDirector
- Lu AlleruzzoExecutive Officer
- Wei R. ChenDirector
- Peter A. JenkinsDirector
- Offering amount
- $3.4M
- Amount sold
- $2.5M
- First sale
- Jun 2014
- Incorporated
- Corporation, Wyoming, 2012
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Immunophotonics, Inc..
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $400K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Immunophotonics, Inc. do?
- Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.
- Who founded Immunophotonics, Inc.?
- Immunophotonics, Inc. was founded by Dr. Hode, Mr. Alleruzzo, Dr. Chen, Dr. Robert Nordquist, Luciano Alleruzzo, Wei Chen in 2012.
- Who are Immunophotonics, Inc.'s investors?
- Immunophotonics, Inc.'s investors include Argonautic Ventures, BioGenerator Ventures, Centennial Investors, iSelect Fund, Missouri Technology Corporation, Cultivation Capital.
- How much funding has Immunophotonics, Inc. raised?
- Immunophotonics, Inc. has disclosed $17.6M raised across 4 rounds.
- Where is Immunophotonics, Inc. headquartered?
- Immunophotonics, Inc. is headquartered in St. Louis, US.